Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C

Bibliographic Details
Title: Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
Authors: Lucía Notario, Marc Cucurull, Gabriela Cerdà, Carolina Sanz, Enric Carcereny, Ana Muñoz-Mármol, Ainhoa Hernández, Marta Domènech, Teresa Morán, Montse Sánchez-Céspedes, Marta Costa, Jose-Luis Mate, Anna Esteve, Maria Saigí
Source: Frontiers in Oncology, Vol 13 (2023)
Publisher Information: Frontiers Media S.A., 2023.
Publication Year: 2023
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: non-small cell lung cancer, lung adenocarcinoma, KRAS, PD-L1, immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who were treated with immunotherapy-based regimens and we evaluated the clinical outcomes according to PD-L1 expression and the type of KRAS mutation. Among all patients included, 47% carried KRAS G12C mutation whereas 53% harbored KRAS non-G12C mutations. PD-L1 status was available for 77% of cases, with higher expression among KRAS G12C tumors (p = 0.01). Better overall survival and progression-free survival were observed in high PD-L1 expression tumors, regardless of KRAS mutation type. The heterogeneous nature of KRAS-mutant tumors and the presence of other co-mutations may contribute to different outcomes to immunotherapy-based strategies.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2023.1239000/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2023.1239000
Access URL: https://doaj.org/article/6460f628e9154bd29ea1ff2e9b47c256
Accession Number: edsdoj.6460f628e9154bd29ea1ff2e9b47c256
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2023.1239000
Published in:Frontiers in Oncology
Language:English